Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

Marlies Antlanger; Oliver Domenig; Christopher C. Kaltenecker; J. Kovarik; Manfred Hecking; Marko Poglitsch; Chantal Kopecky; Markus Säemann; Elisabeth Schwaiger; Martin M. Müller; Vincent Rathkolb

doi:10.1111/dom.14639

Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

Marlies Antlanger
, Oliver Domenig
, Christopher C. Kaltenecker
, J. Kovarik
, Manfred Hecking
, Marko Poglitsch
, Chantal Kopecky
, Markus Säemann
, Elisabeth Schwaiger
, Martin M. Müller
, Vincent Rathkolb

Universitätsklinik für Innere Medizin 2 - Gastroenterologie und Hepatologie, Endokrinologie und Stoffwechsel, Nephrologie, Rheumatologie

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	816-826
Seitenumfang	11
Fachzeitschrift	Diabetes, Obesity and Metabolism
Volume	24
Ausgabenummer	5
DOIs	https://doi.org/10.1111/dom.14639
Publikationsstatus	Veröffentlicht - Mai 2022

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

302016 Gastroenterologie
302025 Hepatologie
302030 Innere Medizin

Zugriff auf Dokument

10.1111/dom.14639

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Antlanger, M., Domenig, O., Kaltenecker, C. C., Kovarik, J., Hecking, M., Poglitsch, M., Kopecky, C., Säemann, M., Schwaiger, E., Müller, M. M., & Rathkolb, V. (2022). Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. Diabetes, Obesity and Metabolism, 24(5), 816-826. https://doi.org/10.1111/dom.14639

Antlanger, Marlies ; Domenig, Oliver ; Kaltenecker, Christopher C. et al. / Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. in: Diabetes, Obesity and Metabolism. 2022 ; Jahrgang/Volume 24, Nr. 5. S. 816-826.

@article{9b3ce648c0164d7780a5f26ea0cc751a,

title = "Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial",

author = "Marlies Antlanger and Oliver Domenig and Kaltenecker, \{Christopher C.\} and J. Kovarik and Manfred Hecking and Marko Poglitsch and Chantal Kopecky and Markus S{\"a}emann and Elisabeth Schwaiger and M{\"u}ller, \{Martin M.\} and Vincent Rathkolb",

year = "2022",

month = may,

doi = "10.1111/dom.14639",

language = "English",

volume = "24",

pages = "816--826",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley",

number = "5",

}

Antlanger, M, Domenig, O, Kaltenecker, CC, Kovarik, J, Hecking, M, Poglitsch, M, Kopecky, C, Säemann, M, Schwaiger, E, Müller, MM & Rathkolb, V 2022, 'Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial', Diabetes, Obesity and Metabolism, Jg. 24, Nr. 5, S. 816-826. https://doi.org/10.1111/dom.14639

Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. / Antlanger, Marlies; Domenig, Oliver; Kaltenecker, Christopher C. et al.
in: Diabetes, Obesity and Metabolism, Volume 24, Nr. 5, 05.2022, S. 816-826.

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

TY - JOUR

T1 - Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial

AU - Antlanger, Marlies

AU - Domenig, Oliver

AU - Kaltenecker, Christopher C.

AU - Kovarik, J.

AU - Hecking, Manfred

AU - Poglitsch, Marko

AU - Kopecky, Chantal

AU - Säemann, Markus

AU - Schwaiger, Elisabeth

AU - Müller, Martin M.

AU - Rathkolb, Vincent

PY - 2022/5

Y1 - 2022/5

UR - https://www.scopus.com/pages/publications/85123589623

U2 - 10.1111/dom.14639

DO - 10.1111/dom.14639

M3 - Article

C2 - 34984822

SN - 1462-8902

VL - 24

SP - 816

EP - 826

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 5

ER -

Antlanger M, Domenig O, Kaltenecker CC, Kovarik J, Hecking M, Poglitsch M et al. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind placebo-controlled exploratory trial. Diabetes, Obesity and Metabolism. 2022 Mai;24(5):816-826. doi: 10.1111/dom.14639